Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Express Scripts
Accenture
QuintilesIMS
Moodys
Johnson and Johnson
Dow
Argus Health

Generated: May 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019618

« Back to Dashboard

NDA 019618 describes SFROWASA, which is a drug marketed by Mylan Speciality Lp and is included in one NDA. It is available from three suppliers. There is one patent protecting this drug. Additional details are available on the SFROWASA profile page.

The generic ingredient in SFROWASA is mesalamine. There are twenty-eight drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mesalamine profile page.
Summary for 019618
Tradename:SFROWASA
Applicant:Mylan Speciality Lp
Ingredient:mesalamine
Patents:1
Therapeutic Class:Inflammatory Bowel Disease Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 019618
Ingredient-typeAminosalicylic Acids
Medical Subject Heading (MeSH) Categories for 019618
Suppliers and Packaging for NDA: 019618
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ROWASA mesalamine ENEMA;RECTAL 019618 NDA Meda Pharmaceuticals 0037-0022 N 0037-0022-07
ROWASA mesalamine ENEMA;RECTAL 019618 NDA Meda Pharmaceuticals 0037-0022 N 0037-0022-14

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:ENEMA;RECTALStrength4GM/60ML
Approval Date:Dec 24, 1987TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:ENEMA;RECTALStrength4GM/60ML
Approval Date:Jun 20, 2008TE:ABRLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jul 24, 2027Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 019618

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Speciality Lp ROWASA mesalamine ENEMA;RECTAL 019618-001 Dec 24, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Speciality Lp ROWASA mesalamine ENEMA;RECTAL 019618-001 Dec 24, 1987 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Express Scripts
Healthtrust
Johnson and Johnson
QuintilesIMS
Citi
Fuji
McKesson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.